Skip to main content

Table 4 Utility of PROMIS-29 domains to identify patients with high Type 1 and high Type 2 SLE activity

From: Using PROMIS-29 to determine symptom burdens in the context of the Type 1 and 2 systemic lupus erythematosus (SLE) model: a cross sectional study

 

Type 1 SLE

Type 2 SLE

All domains

Backward selection

All domains

Backward selection

OR (95% CI)

OR (95% CI)

OR (95% CI)

OR (95% CI)

Depression

1.02 (0.95, 1.09)

–

1.03 (0.84, 1.13)

–

Anxiety

1.00 (0.94, 1.07)

–

0.99 (0.90, 1.09)

–

Social function

1.04 (0.97, 1.11)

–

1.02 (0.93, 1.11)

–

Fatigue

1.02 (0.97, 1.07)

–

1.23 (1.11, 1.35)

1.22 (1.12, 1.32)

Sleep disturbance

1.03 (0.95, 1.12)

–

1.00 (0.87, 1.15)

–

Pain interference

1.01 (0.94, 1.08)

–

1.00 (0.91, 1.09)

–

Physical function

0.92 (0.85, 1.00)

0.93 (0.89, 0.97)

0.91 (0.83, 1.00)

0.92 (0.86, 0.98)

Hit rate

61%

59%

83%

82%

Chance hit rate

52%

52%

51%

51%

Huberty’s I index

0.18

0.15

0.66

0.63

  1. High type 1 SLE was defined as SLE disease activity index (SLEDAI) ≥ 6, Clinical SLEDAI (SLEDAI scored without serologic descriptors) ≥ 4, active nephritis (i.e., evidence of proteinuria, pyuria, or hematuria by SLEDAI criteria), or Type 1 physician global assessment (PGA) ≥ 1; High Type 2 SLE was defined as polysymptomatic distress scale (PSD) ≥ 8 or Type 2 PGA ≥ 1